Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma
Cancer Research and Treatment. 2018;50(3):646-657 
P556 INTER-ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H4 AS DIAGNOSTIC AND PROGNOSTIC INDICATOR IN PATIENTS WITH HEPATITIS B VIRUS ASSOCIATED HEPATOCELLULAR CARCINOMA
Journal of Hepatology. 2014;60(1):S254
Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
Journal of Hepatocellular Carcinoma. 2018;Volume 5:91-98
Inter-alpha inhibitor proteins—biomarker for NEC?
The Journal of Pediatrics. 2010;157(5):A2
Analysis of prognostic factors and treatment outcomes for survival in hepatocellular carcinoma patients
Annals of Oncology. 2019;30:vi130
The tumor diameter cut-off for predicting microscopic intrahepatic metastasis of hepatocellular carcinoma patients without treatment history differs from that of hepatocellular carcinoma patients with a treatment history
Clinical and Translational Oncology. 2019;22(3):319-329
Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy
Cancer. 2002;95(9):2038-2039
Predicting the posttransplant prognosis of patients with hepatocellular carcinoma: What lies beneath alpha-fetoprotein?
Liver Transplantation. 2013;19(10):1166-1167
Serum TGF-β1: A Potential Biomarker for Early Detection of Hepatocellular Carcinoma
EBioMedicine. 2016;12:4-5
Serum lnc34a is a Potential Prediction Biomarker for Bone Metastasis in Hepatocellular Carcinoma Patients
. 2020;